MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

Search

CRISPR Therapeutics AG

Open

SectorGezondheidszorg

69.63 0.03

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

69.46

Max

73.7

Belangrijke statistieken

By Trading Economics

Inkomsten

-73M

-209M

Verkoop

27K

892K

Winstmarge

-23,379.933

Werknemers

393

EBITDA

-59M

-203M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

-4.19% downside

Dividenden

By Dow Jones

Volgende Winsten

4 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

653M

5.8B

Vorige openingsprijs

69.6

Vorige sluitingsprijs

69.63

Nieuwssentiment

By Acuity

50%

50%

149 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

CRISPR Therapeutics AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 okt 2025, 23:30 UTC

Populaire aandelen

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 okt 2025, 21:21 UTC

Winsten

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 okt 2025, 00:00 UTC

Acquisities, Fusies, Overnames

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 okt 2025, 23:40 UTC

Marktinformatie

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 okt 2025, 23:39 UTC

Marktinformatie

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 okt 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 okt 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 okt 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 okt 2025, 23:00 UTC

Marktinformatie

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 okt 2025, 22:54 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Scales's JV Buyout Lauded by Bull -- Market Talk

2 okt 2025, 22:54 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Forex and Fixed Income Roundup: Market Talk

2 okt 2025, 22:46 UTC

Marktinformatie

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 okt 2025, 22:46 UTC

Marktinformatie

Global Equities Roundup: Market Talk

2 okt 2025, 21:17 UTC

Acquisities, Fusies, Overnames

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 okt 2025, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Energy & Utilities Roundup: Market Talk

2 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

2 okt 2025, 20:49 UTC

Acquisities, Fusies, Overnames

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 okt 2025, 20:00 UTC

Acquisities, Fusies, Overnames

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 okt 2025, 19:20 UTC

Marktinformatie

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 okt 2025, 19:10 UTC

Marktinformatie

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 okt 2025, 19:04 UTC

Marktinformatie

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 okt 2025, 18:45 UTC

Acquisities, Fusies, Overnames

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 okt 2025, 18:45 UTC

Acquisities, Fusies, Overnames

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 okt 2025, 18:44 UTC

Acquisities, Fusies, Overnames

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 okt 2025, 18:44 UTC

Acquisities, Fusies, Overnames

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 okt 2025, 18:44 UTC

Acquisities, Fusies, Overnames

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 okt 2025, 18:43 UTC

Acquisities, Fusies, Overnames

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Peer Vergelijking

Prijswijziging

CRISPR Therapeutics AG Prognose

Koersdoel

By TipRanks

-4.19% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 69.77 USD  -4.19%

Hoogste 100 USD

Laagste 40 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor CRISPR Therapeutics AG - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

15 ratings

10

Buy

5

Hold

0

Sell

Technische score

By Trading Central

33.5 / 38.27Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

149 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
help-icon Live chat